25,729 articles
Ftibamzone
Ftibamzone (酞丁安, phthiobuzone, V6133), a thiosemicarbazone topical antiviral developed in China, inhibits viral DNA and early protein synthesis; used for herpes simplex, zoster, trachoma, and condyloma acuminatum, not US-approved.
FU study
FU study (Follow-up Visit of High Risk Infants, NCT00009633): NICHD Neonatal Research Network multi-center cohort following surviving extremely low birth-weight infants with neurodevelopmental assessments at 22-26 months corrected age to identify maternal and neonatal risk factors.
Fuchs heterochromic iridocyclitis
Fuchs heterochromic iridocyclitis, also called Fuchs uveitis syndrome (FUS), is a chronic, usually unilateral, mild anterior uveitis first described by Ernst Fuchs in 1906, marked by stellate keratic precipitates, iris atrophy, and cataract or glaucoma complications.
Fucosidosis
Fucosidosis (alpha-L-fucosidase deficiency, OMIM 230000) is an ultra-rare autosomal recessive lysosomal storage disease caused by FUCA1 mutations, with progressive neurodegeneration, coarse facies, angiokeratomas, and recurrent infections.
Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (复旦大学附属肿瘤医院, FUSCC), founded 1931 as the Sino-Belgian Radium Treatment Hospital, is China's earliest cancer-specialty hospital, a Grade III-A Fudan University affiliate in Shanghai ranked 3rd nationally in oncology.
Fuhrmann syndrome
Fuhrmann syndrome, also called Fuhrmann-Rieger-de Sousa syndrome, is a rare autosomal recessive disorder causing bowed femurs, absent or small fibulae and ulnae, and digit anomalies, caused by WNT7A mutations.
Fukutin-related limb-girdle muscular dystrophy R13
Fukutin-related limb-girdle muscular dystrophy R13 (LGMD R13, LGMD2M) is an autosomal recessive dystroglycanopathy caused by FKTN mutations, with infantile hypotonia, proximal weakness, and cardiomyopathy; prevalence under 1 in 1,000,000.
Fulguration
Fulguration is a non-contact electrosurgery technique in which an electrode held slightly off the skin throws sparks that destroy abnormal tissue superficially, named for the Latin word for lightning.
Full schwannomatosis
Full schwannomatosis is a rare, fully expressed form of neurofibromatosis marked by multiple benign nerve sheath tumors that usually spare the vestibular nerves and often cause severe chronic pain.
Full sternotomy
A full sternotomy is an operation in which the sternum is divided lengthwise in the midline, giving wide access to the heart and great vessels for open cardiac surgery.
Full-field electroretinography
Full-field electroretinography (ffERG) is a clinical electrophysiological test recording the whole retina's electrical response to light flashes, separating rod from cone function to diagnose retinal dystrophies.
Full-thickness resection
Full-thickness resection (FTR) is an endoscopic technique that removes a gastrointestinal lesion with all layers of the bowel or stomach wall, used for polyps and tumors that mucosal techniques cannot remove.
Fullerene drug delivery
Fullerene drug delivery is the use of fullerene cages, most often the 60-carbon C60 buckyball, as nanoscale carriers that deliver drugs to target tissues, especially in combined chemo-photodynamic cancer therapy.
Fulminant viral hepatitis
Fulminant viral hepatitis is rapid, severe acute liver failure with encephalopathy developing within 8 weeks of jaundice, caused mainly by hepatitis B and also hepatitis A.
Fulranumab
Fulranumab (AMG 403, JNJ-42160443) is a human IgG2 monoclonal antibody neutralizing nerve growth factor, developed by Janssen and Amgen for osteoarthritis and chronic pain; it reached phase 3 but was discontinued in 2016 after joint-safety concerns and assay artifacts.
Fulvestrant regimen
The fulvestrant regimen is a hormonal cancer treatment for hormone receptor-positive advanced breast cancer, in which fulvestrant 500 mg is injected monthly, alone or combined with the CDK4/6 inhibitor abemaciclib.
Fulzerasib (GFH925, IBI351)
Fulzerasib (GFH925, IBI351; Dupert, 达伯特) is an oral covalent KRAS G12C inhibitor from GenFleet/Innovent, approved by China's NMPA in August 2024 for previously treated advanced KRAS G12C-mutant NSCLC, with phase 2 ORR 49.1% and mPFS 9.7 months.
Functional abdominal pain syndrome
Functional abdominal pain syndrome (FAPS), renamed centrally mediated abdominal pain syndrome (CAPS) in Rome IV, is a chronic gut-brain interaction disorder with continuous abdominal pain unrelated to eating, defecation, or menses, lasting at least 6 months and limiting daily function.
Functional anorectal disorders
Functional anorectal disorders are chronic anorectal conditions not explained by structural disease, defined by the Rome IV criteria and classified as fecal incontinence, anorectal pain, and functional defecation disorders.
Functional anorectal pain
Functional anorectal pain (ICD-11 DD92.1) is pain of the rectum or anus without structural cause, classified by Rome IV as levator ani syndrome, unspecified functional anorectal pain, or proctalgia fugax.
Functional connectivity analysis
Functional connectivity analysis measures statistical relationships, most commonly temporal correlations, between activity in different brain regions, typically from resting-state fMRI, and is used in clinical research on brain disorders.
Functional connectivity MRI
Functional connectivity MRI, also called resting-state fMRI, is an MRI method that maps brain networks by measuring correlations of spontaneous BOLD signal fluctuations between regions, without any task or stimulus.
Functional defaecation disorders
Functional defaecation disorders (FDDs, Rome IV category F3; ICD-11 DD92.2) are gut-brain interaction disorders with impaired rectal evacuation, subtypes inadequate defecatory propulsion and dyssynergic defecation, diagnosed by 2 of 3 physiological tests and treated with biofeedback.
Functional diarrhoea
Functional diarrhoea (FDr, ICD-11 DD91.2) is a gut-brain disorder of chronic loose or watery stools in over 25% of stools without predominant abdominal pain, distinguished from IBS-D and diagnosed with limited testing.
Functional dyspepsia
Functional dyspepsia (FD) is a gut-brain interaction disorder causing recurrent upper abdominal symptoms without structural disease, affecting 5-10% of people, diagnosed by Rome criteria, with subtypes PDS and EPS and treatments including TCAs and prokinetics.
Functional electrical stimulation
Functional electrical stimulation (FES) applies electrical pulses to intact peripheral motor nerves to produce coordinated muscle contractions for useful movements such as walking, grasping, or cycling, used in spinal cord injury and stroke.
Functional family therapy
Functional family therapy (FFT) is a short-term, family-based treatment for adolescents with behavioral problems such as delinquency and substance use, developed at the University of Utah in 1969.
Functional Food
Functional food: foods offering health benefits beyond basic nutrition, also called nutraceuticals or designer foods. No legal definition in EU or US; concept from Japan's 1984 project and FOSHU system; regulated via health-claim frameworks.
Functional gallbladder disorder
Functional gallbladder disorder, also called biliary dyskinesia or chronic acalculous cholecystitis, is biliary pain without gallstones or structural pathology, diagnosed by Rome IV criteria and HIDA ejection fraction, and often treated with cholecystectomy of uncertain benefit.
Functional gastrointestinal disorder
Functional gastrointestinal disorder (FGID), now disorders of gut-brain interaction (DGBI), chronic GI symptom syndromes diagnosed by Rome criteria; over 40% global prevalence, renamed by Rome IV 2016, Rome V 2026.